AIEQ1.420%
as of Oct 26
TECH
GrowthBio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
Close · 3M
+39.55%
Held by 1 AI ETF
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals7
Win rate100% (6/6)
Avg buy return+9.32%
AIEQ · Weight increase · 2d
weight 1.390% → 1.420% (+0.030 pp)·stock down 0.0% in the 30 days before
Oct 25·now $72.55
price n/a
AIEQ · Weight decrease · 2d
weight 1.400% → 1.370% (-0.030 pp)·stock up 0.3% in the 30 days before
Oct 7·entry $72.53·now $72.55
+0.03%
since Oct 7
AIEQ · Sudden change · 1d
weight 0.050% → 1.410% (+1.360 pp)·stock up 0.3% in the 30 days before
Oct 1·entry $72.40·now $72.55
+0.21%
since Oct 1
AIEQ · New entry · 1d
weight 0 → 0.050% (new)·stock up 0.8% in the 30 days before
Sep 1·entry $72.18·now $72.55Fresh
+0.51%
since Sep 1
AIEQ · Exit · 1d
weight 0.450% → 0 (exited)·stock up 1.5% in the 30 days before
Aug 2·entry $72.14·now $72.55
+0.57%
since Aug 2
AIEQ · New entry · 1d
weight 0 → 0.450% (new)·stock up 39.8% in the 30 days before
Jul 1·entry $71.00·now $72.55Drifting
+2.18%
since Jul 1
AIVL · Exit · 1d
weight 0.287% → 0 (exited)·stock up 36.7% in the 30 days before
Jun 30·entry $70.65·now $72.55
+2.69%
since Jun 30
AIVL · Accumulation · 6d
weight 0.222% → 0.287% (+0.065 pp)·stock up 47.6% in the 30 days before
Jun 26·entry $71.00·now $72.55Drifting
+2.18%
since Jun 26
AIVL · Accumulation · 5d
weight 0.225% → 0.285% (+0.061 pp)·stock up 47.4% in the 30 days before
Jun 25·entry $70.70·now $72.55Drifting
+2.62%
since Jun 25
AIVL · Accumulation · 5d
weight 0.223% → 0.241% (+0.019 pp)·stock up 22.1% in the 30 days before
Jun 24·entry $58.88·now $72.55Chased
+23.22%
since Jun 24
AIVL · Weight increase · 2d
weight 0.222% → 0.238% (+0.015 pp)·stock up 27.4% in the 30 days before
Jun 18·entry $57.94·now $72.55Chased
+25.22%
since Jun 18
AIVL · Weight decrease · 2d
weight 0.218% → 0.202% (-0.017 pp)·stock down 14.6% in the 30 days before
May 11·entry $47.42·now $72.55
+52.99%
since May 11
AIVL · Weight decrease · 2d
weight 0.238% → 0.227% (-0.011 pp)·stock down 0.2% in the 30 days before
Apr 29·entry $51.95·now $72.55
+39.65%
since Apr 29
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Fails the frameworkas of Oct 25
AIEQ is slowly accumulating, adding 0.03pp to reach a 1.42% weight, which signals mild conviction in a recovery in life-science tools demand. The Buffett-style read conflicts with this, because a sub-10% ROE, stagnant revenue and a very high multiple fail both the financial-health and margin-of-safety tests. The tiny size of the increase suggests the AI is making a modest, momentum or sector-based bet rather than a value call.
- Circle of CompetenceBio-Techne sells reagents, proteins, antibodies and instruments to research and diagnostics customers, a recurring-consumables model whose unit economics are reasonably predictable over ten years, though academic and biotech funding cycles add some noise.
- Economic MoatIts catalog of widely cited research proteins and antibodies creates switching costs and brand trust among scientists, a moderately durable advantage, though less dominant than the largest tools peers.
- ManagementCandor and capital allocation cannot be judged from the data given, and the acquisition-heavy history and flat revenue leave the record of returns on deals unproven here.
- Financial HealthA current ROE of 8.9% falls below the 15% threshold, and with revenue down 0.38% YoY there is no evidence of the consistent high returns on equity capital that the framework requires.
- Margin of SafetyAt 62.6 times earnings and 43 times EV/EBITDA with no growth, the price leaves no margin of safety, since owner earnings would have to expand far beyond current levels to justify it.
Bio-Techne is an understandable business with a respectable consumables moat, so it clears the circle of competence and moat stages. It fails on low returns on equity and a price that offers no margin of safety, and management quality cannot be verified from this data. The business may be good, but at this valuation the framework would pass on it.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.